Business Wire

Hillstone Networks Acknowledged as an XDR Leader in Frost Radar™ 2023 Report

13.9.2023 09:00:00 EEST | Business Wire | Press release

Share

Hillstone Networks, a leading provider of cybersecurity solutions, has been named an innovation and growth leader in the 2023 Frost Radar™ Extended Detection and Response Report.

The Frost Radar™ 2023 Report is a market analysis conducted by Frost & Sullivan, evaluating industry participants based on their growth strategy, innovation, customer experience, and market share. The report aims to assist organizations in making informed decisions when selecting a reliable XDR solution provider.

“Our inclusion as a leader in the Frost Radar™ 2023 Report reaffirms our dedication to deliver cutting-edge solutions that effectively counter evolving digital threats,” states Tim Liu, CTO and Co-founder at Hillstone Networks. “Our solution integrates advanced threat detection, incident response, and forensic capabilities into a unified platform, empowering businesses to proactively safeguard their digital assets.”

According to Frost & Sullivan, XDR solutions have seen rapid expansion across geographies, industries, and companies of all sizes as it delivers the visibility, integration, analytics, flexibility, and automation that customers need in today’s complex IT environments. Frost states that XDR has three core promises: cross-layered detection and response, meaningful automation, and integration with the security stack.

"Hillstone Networks shows commitment to the Open XDR approach, as it is investing its significant R&D budget in increasing third-party integrations and providing software development kits (SDKs) to facilitate integration with its platform,” states Lucas Ferreyra, Industry Analyst at Frost & Sullivan. “Hillstone Networks has developed a compelling growth strategy, that involves leveraging the increasing relevance of managed security to allow MSSPs to use its XDR solution, broadening its reach while targeting high-growth sectors such as government, healthcare, education, and manufacturing. Such understanding of the market will allow Hillstone Networks to unlock further growth opportunities in the extremely competitive market of XDR.”

Hillstone’s commitment to continuous innovation and successful customer deployments contributes to its emergence as a frontrunner in the XDR domain, as well as delivering on the core promises of XDR:

  • Hillstone’s AI-powered threat detection and response capabilities can find and mitigate attacks before they have a chance to exploit the most vital asset in the enterprise – data. The Hillstone XDR solution uses advanced machine learning (ML) algorithms through unknown malware and abnormal detection, advanced threat correlation analytics, and automatic threat mitigation.
  • Hillstone XDR also includes automated orchestration and response. If a remediation strategy has been configured, once a threat is identified, Hillstone XDR will automatically execute the appropriate mitigation actions according to a predefined playbook.
  • It includes integration with a wide variety of data across the full spectrum of the network, from endpoints to cloud. This data can include NetFlow, Sysmon, Syslogs, metadata, threat information and third-party logs, all of which are then standardized, correlated, and analyzed to provide complete visibility and break down security information silos. It not only brings full security visibility with far fewer blind spots, but also improves detection accuracy by minimizing false positives.

Learn more about Hillstone XDR here.

About Hillstone Networks

Hillstone Networks is a leader in cybersecurity, delivering both depth and breadth of protection to companies of all sizes, from edge to cloud, and across any workload. Hillstone Networks’ Integrative Cyber Security approach brings coverage, control, and consolidation to more than 26,000 enterprises worldwide. www.hillstonenet.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zeyao Hu
+1 4085086750
inquiry@hillstonenet.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye